Get started
Author

G. S. Nowakowski

Observed names: G S Nowakowski, G. Nowakowski, G.S. Nowakowski, Gregorz Nowakowski, Gregorz S Nowakowski, Gregorz S. Nowakowski, Nowakowski, Gregorz S
Institution: Mayo Clinic
OpenAlex ID: A5043863383
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma
2011 · L. F. Porrata, K. Ristow, et al. · Haematologica · 208
PDF
Pulmonary langerhans cell histiocytosis
2012 · Harpreet S Suri, Eunhee S Yi, et al. · Orphanet Journal of Rare Diseases · 160
PDF
The molecular basis for the cytokine-induced defect in homing and engraftment of hematopoietic stem cells
2001 · Virla M Berrios, Gerri J Dooner, et al. · Experimental Hematology · 76
PDF
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma
2010 · L F Porrata, K Rsitow, et al. · Leukemia · 55
Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma
2015 · Matthew J. Maurer, Jean‐Philippe Jais, et al. · American Journal of Hematology · 49
PDF
Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells
2016 · H Ding, K L Peterson, et al. · Leukemia · 39
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials
2018 · A. Castellino, A. Chiappella, et al. · Blood Cancer Journal · 37
PDF
Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma
2017 · S I Tracy, M J Maurer, et al. · Blood Cancer Journal · 34
PDF
High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)
2017 · T E Witzig, B LaPlant, et al. · Blood Cancer Journal · 18
PDF
OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY
2019 · M.J. Maurer, L.H. Jakopsen, et al. · Hematological Oncology · 3
Multicohort Study of Conditional Survival and Cause of Death After Achieving Event‐Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL)
2023 · Y. Wang, M. C. Larson, et al. · Hematological Oncology · 1
PDF
Single-agent lenalidomide for newly diagnosed myeloma with on-demand dexamethasone: A phase II trial.
2011 · F. Buadi, M. Lacy, et al. · Journal of Clinical Oncology · 1
224 | Regular Aspirin Use Prior to Diagnosis and Follicular Lymphoma Prognosis: Novel Association With Superior Event‐free Survival
2025 · G. Cholack, R. Mwangi, et al. · Hematological Oncology
PDF
Pb2110: Pharmacokinetics and Pharmacodynamics in First-mind: a Phase Ib, Open-label, Randomized Study of Tafasitamab ± Lenalidomide + R-chop in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
2022 · D. Belada, K. Kopeckova, et al. · HemaSphere
Interim Pet/ct Predicts Outcomes of Diffuse Large B‐cell Lymphoma (dlbcl) Treated With Frontline Lenalidomide/rchop (r2chop): Long‐term Analysis of Mc078e
2021 · S. Desai, B. Laplant, et al. · Hematological Oncology
PDF
Ps1249 Extranodal and Spleen Disease Detected by Fdg‐pet/ct Is Associated With Early Clinical Failure in Untreated Follicular Lymphoma
2019 · F. St‐Pierre, S. Broski, et al. · HemaSphere
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.
2016 · Maurer, Matthew J, Jais, Jean-Philippe, et al. · HAL (Le Centre pour la Communication Scientifique Directe)
IPI24 supplemental material submitted
2015 · M. J. Maurer, J. P. Jais, et al.
A single heptapeptide from a phage display peptide library homes to bone marrow in vivo and binds to primitive murine stem cells
2000 · G.S. Nowakowski, V.M. Berrios, et al. · Experimental Hematology
Works count: 19
Citation count: 681
H-index: 9
I10-index: 9
Year
Topic
Type